Pyxis Oncology, Inc. (NASDAQ:PYXS) Receives Average Rating of “Moderate Buy” from Brokerages

Shares of Pyxis Oncology, Inc. (NASDAQ:PYXS) have been assigned an average rating of “Moderate Buy” from the seven ratings firms that are presently covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and five have given a buy rating to the company. The average 12 month price objective among analysts that have updated their coverage on the stock in the last year is $7.20.

A number of research analysts have issued reports on PYXS shares. Guggenheim lifted their target price on Pyxis Oncology from $5.00 to $7.00 and gave the company a “buy” rating in a research report on Tuesday, November 4th. HC Wainwright lifted their price target on shares of Pyxis Oncology from $5.00 to $7.00 and gave the company a “buy” rating in a report on Friday, December 19th. Royal Bank Of Canada dropped their price objective on shares of Pyxis Oncology from $8.00 to $5.00 and set an “outperform” rating for the company in a research note on Thursday, December 18th. Zacks Research cut shares of Pyxis Oncology from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, November 4th. Finally, Stifel Nicolaus initiated coverage on shares of Pyxis Oncology in a report on Monday, November 3rd. They set a “buy” rating and a $9.00 price target for the company.

Pyxis Oncology Price Performance

Shares of PYXS opened at $1.45 on Tuesday. The firm has a 50 day simple moving average of $2.56 and a two-hundred day simple moving average of $2.44. Pyxis Oncology has a one year low of $0.83 and a one year high of $5.55. The company has a market cap of $90.28 million, a P/E ratio of -0.91 and a beta of 1.44.

Pyxis Oncology (NASDAQ:PYXS) last issued its quarterly earnings results on Monday, November 3rd. The company reported ($0.35) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.36) by $0.01. On average, analysts expect that Pyxis Oncology will post -1.04 earnings per share for the current fiscal year.

Institutional Trading of Pyxis Oncology

A number of hedge funds have recently made changes to their positions in PYXS. Schulhoff & Co. Inc. increased its stake in shares of Pyxis Oncology by 125.4% in the second quarter. Schulhoff & Co. Inc. now owns 275,000 shares of the company’s stock valued at $302,000 after buying an additional 153,000 shares during the period. Y Intercept Hong Kong Ltd acquired a new stake in Pyxis Oncology during the 2nd quarter worth approximately $146,000. Catalyst Funds Management Pty Ltd bought a new stake in Pyxis Oncology during the 2nd quarter worth approximately $26,000. Bridgeway Capital Management LLC increased its position in Pyxis Oncology by 76.1% in the 2nd quarter. Bridgeway Capital Management LLC now owns 142,295 shares of the company’s stock valued at $157,000 after acquiring an additional 61,500 shares during the period. Finally, Jane Street Group LLC acquired a new position in Pyxis Oncology in the 2nd quarter valued at approximately $370,000. 39.09% of the stock is owned by institutional investors and hedge funds.

About Pyxis Oncology

Pyxis Oncology (NASDAQ: PYXS) is a clinical?stage biotechnology company focused on the discovery and development of targeted oncology therapies. The company’s platform centers on antibody?drug conjugates (ADCs) that deliver potent mitotic inhibitors directly to cancer cells, leveraging novel payloads designed to disrupt cell division. By combining highly specific antibodies with innovative cytotoxic agents, Pyxis Oncology aims to improve therapeutic windows and reduce off?target toxicities common to conventional chemotherapies.

Since its inception, Pyxis Oncology has built a pipeline of early?stage ADC candidates directed against a variety of solid tumor antigens.